AAA
CMPX icon

Affinity Asset Advisors’s Compass Therapeutics CMPX Stock Holding History

Affinity Asset Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-130,807
Closed -$249K – 95
2025
Q1 		$249K Buy
+130,807
New +$348K 0.02% 90

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Affinity Asset Advisors's CMPX Position: Q2 2025 in Review

Affinity Asset Advisors sold out of Compass Therapeutics (CMPX) in Q2 2025, closing a stake of 130,807 shares — an estimated $249K sold.

Affinity Asset Advisors first reported a position in CMPX in Q1 2025 and held it in 1 quarter. The position peaked at $249K in Q1 2025. 103 funds tracked by Wall St. Rank hold CMPX as of Q2 2025.

  • Affinity Asset Advisors reported no remaining Compass Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 130,807 Compass Therapeutics shares in Q2 2025, an estimated $249K.
  • Affinity Asset Advisors first reported a position in Compass Therapeutics in Q1 2025 and held it in 1 quarter.
  • Affinity Asset Advisors's Compass Therapeutics position peaked at $249K in Q1 2025.
  • 103 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2025.

Based on Affinity Asset Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.